Study of Pridopidine for the Treatment of Participants With Huntington's Disease

- Huntington Disease
- Completed

Study Title: A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease

Teva Identifier: ACR16 C009

ClinicalTrials.gov Identifier: NCT00724048

Study Status: Completed

Trial Condition(s): Huntington Disease

Interventions: Drug: ACR16 10 mg | Drug: ACR16 22.5 mg | Drug: ACR16 45 mg | Other: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 30 Years and older

Trial Duration: 10/01/2008 - 06/01/2011

Phase: Phase 2/3

Study Type

Interventional